secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2024-12-04T23:59:59+00:00
Accession:  0001104659-24-125350
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics CEO Russell Trenary resigns effective Dec 3; CFO Kenyon named interim CEO
--------------------------------------------------------------------------------

- C. Russell Trenary III stepped down as President, CEO and Board member on Dec 3, 2024, effective immediately.
- Departure is a termination without cause; Trenary will receive severance benefits per his employment agreement.
- Board reduced from ten to nine directors upon Trenary's resignation.
- CFO Lawrence A. Kenyon, 59, appointed Interim CEO effective Dec 3 while Board searches for permanent CEO.
- Kenyon continues as CFO during the interim period; no material arrangements or family relationships disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924125350/0001104659-24-125350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924125350/tm2430072d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-125350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer